A team headed by Angel R. Nebreda at the Institute for Research in Biomedicine (IRB) identifies a dual role of the p38 protein in colon cancer. The study demonstrates that, on the one hand, p38 is important for the optimal maintenance of the epithelial barrier that protects the intestine against toxic agents, thus contributing to decreased tumor development. Intriguingly, on the other hand, once a tumor has formed, p38 is required for the survival and proliferation of colon cancer cells, thus favoring tumor growth. The study is published today in Cancer Cell, a journal with one of the highest impact factors in cancer research.
p38 enhances the survival of colon cancer cells
The protein p38 is a member of the MAPK family -- molecules that transmit signals from outside the cell inside, thus allowing an appropriate and dynamic cell response. This protein is expressed in all cells of the body and it performs highly diverse functions depending on the context and tissue involved. Nebreda's group at IRB focuses on the function of p38 in cancer. Their work describes the essential role of p38 in tumor progression for the first time in vivo. Furthermore, the scientists demonstrate that the treatment of mice with a p38 inhibitor previously used in clinical assays causes a considerable reduction in tumor size. The study provides useful information for clinicians and pharmaceutical companies about the role of p38 in the context of colon cancer. Colorectal cancer is now the second leading cause of cancer-related death in the world.
"p38 inhibitors may have clinical applications, but probably -- and this forms part of the medicine of the future -- these will be in combination with other drugs. We are trying to find out what p38 inhibitors should be combined with to make the tumor, which is now smaller, finally disappear," explains the Spanish scientist Nebreda, head of the Signalling and Cell Cycle Lab at IRB, BBVA Foundation Cancer Research Professor and ICREA research professor.
p38 suppresses pre-tumoral stages characterized by colon inflammation
The role of p38 in cancer is not clear cut. In this same study, Indian-born Jalaj Gupta who recently obtained his PhD in Nebreda's lab and is first author of the work, demonstrates that this same protein in a pre-tumoral context, favoured by inflammation of the colon -- also known as colitis -- impedes tumor development. It is well-known that patients with chronic inflammation of the intestine, such as that caused by Crohn's disease, have a greater incidence of colon tumors that the healthy population. In order to study the relationship between inflammation and cancer, Nebreda's team use mouse models that reproduce this inflammatory context. "Given that p38 regulates inflammation and also functions as a tumor suppressor in some mouse models, our study addressed how these two functions are integrated during the colon tumorigenesis associated with inflammation," says Gupta.
An important finding of the present study is related to the contribution of p38 to the maintenance of an intact epithelial barrier, a structure that protects the intestine from toxic agents and pathogens. Mice genetically depleted of p38 in the epithelial cells that form the intestinal barrier were subjected to a cancer-inducing protocol that causes mutations and inflammation. These animals developed twice as many tumors as a group of p38-expressing mice subjected to the same protocol. The tumor-suppressing capacity of p38 has also been described in cancer of the liver and lung. "Our study highlights the complexity of p38 functions, both in cancer and in the normal maintenance of tissues, and shows why an inhibitor of this molecule could effectively have undesirable side effects. This is why it is necessary to study in depth the patients and contexts in which treatment with such inhibitors would be suitable," explains Gupta.
"All drugs currently used to treat cancer have side effects," states Nebreda, "and in this regard p38 inhibitors would be no exception. However, the administration of such inhibitors to colon cancer patients may be a useful strategy to shrink the tumor in a few days before its surgical removal." Nebreda goes on to explain that the basic research performed in his lab seeks to understand better the biology of tumor cells, the roles of the molecules involved and the mechanisms that allow tumor progression. "We try to take this basic information a step further so that it becomes clinically useful when designing new treatments," says the researcher, who joined IRB, in Barcelona, in 2010, after working in USA, UK, Germany and the CNIO in Madrid.
In collaboration with a team led by Manuel Hidalgo at the CNIO, Nebreda's group is now studying mice implanted with tumors taken from patients. The preliminary results confirm the relevance of p38 for the growth of human tumors. The researchers also have experiments underway to study the involvement of p38 in the progression of breast and lung tumors.
The above story is based on materials provided by Institute for Research in Biomedicine (IRB Barcelona). Note: Materials may be edited for content and length.
Cite This Page: